RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program

• click to rate

  Posted by Two Blokes Jul 9 - Filed in Stock - 4 views
  
  Recursion Pharmaceuticals stock jumps after securing full rights to REV102, aiming to fast-track the first oral therapy for hypophosphatasia.